发明名称 |
METHOD OF OPTIMIZING THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS |
摘要 |
The present invention provides a method of treating Philadelphia positive (Ph+) leukemia, such as Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia (CML), in a human patient population comprising the steps of (a) administering a predetermined fixed amount of a Bcr-Abl tyrosine kinase inhibitor, such as Imatinib, or a pharmaceutically acceptable salt thereof to human patients suffering from a Ph+ leukemia, (b) collecting at least one blood sample from said patients, (c) determining the plasma trough level (Cmin) of the Bcr-Abl tyrosine kinase inhibitor or of a metabolite thereof as well as the MMR rates, (d) assessing a discrimination potential of trough plasma concentrations for MMR and identifying a Cmin threshold for optimal sensitivity and specificity and (e) adjusting the dose of the inhibitor of the Bcr-Abl tyrosine kinase or a pharmaceutically acceptable salt thereof applied to the individual patients from said patient population and, optionally, future patients suffering from a Ph+ leukemia in a manner that a Cmin is achieved in each single patient equal to or higher than the Cmin threshold obtained under step (d). |
申请公布号 |
WO2008036792(A2) |
申请公布日期 |
2008.03.27 |
申请号 |
WO2007US78978 |
申请日期 |
2007.09.20 |
申请人 |
NOVARTIS AG;GATHMANN, INSA;MAHON, FRANCOIS-XAVIER;MOLIMARD, MATHIEU;PICARD, STEPHANE;WANG, YANFENG |
发明人 |
GATHMANN, INSA;MAHON, FRANCOIS-XAVIER;MOLIMARD, MATHIEU;PICARD, STEPHANE;WANG, YANFENG |
分类号 |
A61K49/00;A61K31/00;A61K31/506;A61P35/02 |
主分类号 |
A61K49/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|